Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Deoxycytidine
  • Enhancer Elements, Genetic
  • Fluorouracil
  • Pancreatic Neoplasms
  • Thymidylate Synthase

abstract

  • To our knowledge, this study represents the first genotype-directed clinical trial for patients with pancreatic adenocarcinoma. Although the study was closed early, it appears capecitabine therapy in pancreatic cancer patients harboring the TYMS *2/*2 variant may be associated with increased non-hematologic toxicity. This study also demonstrates the challenges performing a genotype-directed study in the second-line setting for patients with advanced pancreatic cancer.

publication date

  • October 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3110647

Digital Object Identifier (DOI)

  • 10.1007/s10637-010-9413-7

PubMed ID

  • 20306339

Additional Document Info

start page

  • 1057

end page

  • 65

volume

  • 29

number

  • 5